High-dose-rate (HDR) prostate brachytherapy, as performed at our institution, requires the insertion of multiple transperineal catheters under anaesthesia (hereafter referred to as the 'intraoperative' period), after which the patient is allowed to recover from anaesthesia and the treatment is planned and carried out with afterloading of the radioactive source in several treatment sessions over the course of two days (hereafter the 'postoperative' period). The catheters are kept in position by a template sutured to the perineum. At the time of introduction of this new therapy at our institution, we assumed the catheters themselves, the template and the urinary catheter, along with potential bladder spasm, would cause at least moderate pain.
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Prior to the commencement of our prostate brachytherapy program, the principal anaesthetist (JAL) consulted colleagues locally and elsewhere who were involved in prostate brachytherapy and found that techniques varied widely, but included spinal/epidural anaesthesia and subsequently epidural analgesia for the duration of the treatment period or general anaesthesia followed by patientcontrolled intravenous opioid analgesia (PCA). Very few published reports regarding HDR prostate brachytherapy discuss analgesic techniques [1] [2] [3] . We chose a simple regimen of regular paracetamol with supplementary oral or subcutaneous opioids as required, primarily because the nurses of the relevant ward were not accredited at the time to manage more complex techniques.
In order to assess the adequacy of the analgesic regimen, we audited the analgesic, anti-emetic and anti-spasmodic drug usage of our patients undergoing HDR brachytherapy for prostate cancer.
SUMMARy
We audited the analgesic, anti-emetic and anti-spasmodic drug usage of patients undergoing high-dose-rate brachytherapy for prostate cancer at the Royal Prince Alfred Hospital. With institutional ethics committee approval, we retrospectively reviewed the records of the first 45 patients undergoing high-dose-rate prostate brachytherapy from January 2003 to July 2005. We collected data regarding the dose of intra-and postoperative analgesics and the anti-emetic and anti-spasmodic drugs administered for the duration of the patients' hospital stay. We converted oral oxycodone doses to parenteral morphine equivalents for the purposes of this study, dividing the oxycodone dose by three.
The median age of the patients was 69 (range 55 to 80) years. All had general anaesthesia for the catheter insertion procedure. Twenty-five patients (56%) received intraoperative morphine from 5 to 12 mg (mean 9 mg). Forty-three patients (96%) received regular postoperative paracetamol (1 g qid). Thirty-six patients (80%) required additional postoperative opioid administration with an overall mean (all 45 patients included) of 14.5 mg of parenteral morphine equivalents over the entire postoperative course. Thirty-nine patients received intraoperative hyoscine butylbromide to reduce bladder spasm. Fourteen patients were administered antiemetics.
These findings indicate that analgesic requirements during the period in which the prostate brachytherapy catheters remained in place were minimal in most cases. Simple analgesic regimens (regular oral paracetamol, antispasmodics as required for bladder spasm and oral/subcutaneous opioids as required) appear to have been adequate for our patients. 
MeTHoDS
With institutional ethics committee approval, we retrospectively reviewed the medical records of the first 45 patients undergoing HDR prostate brachytherapy over the period January 2003 to July 2005. We collected data regarding the dose of intra-and postoperative analgesics and the antiemetic and anti-spasmodic drugs administered for the duration of the hospital stay, which was three nights for all patients. We converted oral opioid (oxycodone) doses to parenteral morphine equivalents for the purposes of this study, dividing the oxycodone dose by three (a standard conversion factor for oxycodone 4 ).
There was no formal objective assessment of pain or postoperative nausea and vomiting (PoNV) carried out during the treatment or for the purposes of this audit. During their admission, all patients were visited at least once by the anaesthetist (JAL). The patients also spent all of the first day (that of the insertion procedure, scanning, planning and first radiation dose) and most of the second (during which two doses of radiation were administered) in the radiation oncology department where they had near one-on-one nursing care and frequent contact with the senior radiation oncologist (GH) who also enquired regularly about pain. Analgesia was not administered according to any specific protocol but on an 'as-required' basis. our patients could also be given hyoscine butylbromide as required for bladder spasm and anti-emetics according to an institutional protocol for PoNV.
Statistical analysis is descriptive.
ReSULTS
The median age of the patients was 69 (minimum 55, maximum 80) years. All patients had general anaesthesia (thiopentone 1 mg/kg approximately, then sevoflurane in 50 to 66% nitrous oxide in oxygen) for the catheter insertion procedure that was carried out by a single radiation oncologist (GH). Twenty-five patients (56%) received intraoperative morphine from 5 to 12 mg (mean 9 mg), the rest having no intraoperative opioid or other analgesic agent apart from paracetamol. Forty-three patients (96%) received regular postoperative paracetamol (1 g four times a day). Thirty-six patients (80%) required additional postoperative opioid administration with an overall mean (all 45 patients included) of 14.5 mg of parenteral morphine equivalents over the entire postoperative course. The remaining 20% requested no postoperative analgesia whatsoever apart from regular paracetamol.
Of the 25 patients who received intraoperative morphine, seven (28%) requested no additional opioid postoperatively at all, compared to two of the 20 patients (10%) who had no intra-operative opioid administered. Those who received intraoperative morphine used a mean of 12 mg morphine equivalents compared to 18 mg for those having no intra-operative opioids.
The first 35 patients received intra-operative dexamethasone 8 mg, at the request of the radiation oncologist, to help prevent prostate swelling, and this may have also acted as an anti-emetic. This was abandoned after prostate swelling proved not to be problematic. Fourteen patients were administered postoperative anti-emetics at some stage in the course of their treatment, mostly in the early postoperative phase. Three needed more than a single dose (altogether) and only one needed more than two doses, requiring five doses of anti-emetic over two days.
Thirty-nine patients received hyoscine butylbromide intraoperatively to reduce or prevent bladder spasm, found to be an early postoperative problem in some patients early in the series. Four patients received a second dose in the recovery period and four more on the second day.
All patients received thrombo-prophylaxis with enoxaparin daily.
DISCUSSIoN
We were somewhat surprised to find after our first few cases that pain appeared to be a relatively minor aspect of the therapy, the strict immobility for two days being more of an issue for the patients. Analgesic requirements were much less than we expected, some patients requesting no opioid or any other analgesic other than regular paracetamol.
As with pain, PoNV appears to have been a minor issue, with the majority of patients requiring no anti-emetic at any stage. This is probably consistent with the minimal opioid usage. The one patient with more severe PoNV used no postoperative opioid analgesia at all, implying that his PoNV was not analgesia-related.
The minimal use of hyoscine butylbromide after the initial intraoperative dose suggests that for the majority of patients, significant bladder spasm was, if present, limited to the immediate postoperative period, although nursing staff may have interpreted spasm as general pain and administered opioid instead.
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Anaesthesia and Intensive Care, Vol. 36, No. 5, September 2008 Our findings contrast with the study of Colella et al 3 in which it was found that the patients were dissatisfied with the analgesia provided by morphine PCA and the situation improved after the introduction of patient-controlled epidural analgesia (PCeA) with bupivacaine and fentanyl. In that study however, the mean pain scores were all less than 4/10, the worst pain being that associated with the presence of the indwelling urinary catheter. They do not mention the use of anything other than PCA or PCeA for analgesia. The addition of regular paracetamol may have been beneficial in those circumstances, possibly avoiding the need to increase the morphine PCA dose or escalate management to the more invasive PCeA technique.
A significant limitation of this study is the lack of objective pain or PoNV assessment. Another limitation is the fact that administration of analgesia was not protocol driven and we cannot exclude the possibility the patients had significant pain and either did not request or were not offered analgesia. Subjective assessment did however, occur frequently, at least during the long periods while the patients were in the radiation oncology department. It seems therefore unlikely that the patients had pain that was under-treated but this is still possible. In no case, however, did the patient indicate during the post-anaesthetic follow-up visits that the pain had been severe or that the analgesia prescribed had been inadequate or withheld when required. In an independent study, the first 26 of our patients were also assessed for pain as part of a prospective survey of the patients' overall experience conducted across two institutions by our radiation therapists (data unpublished to date). In that study, 22% of the patients rated their pain greater than mild on the first day and 10% on the second. This supports our subjective assessment that pain appeared to be a relatively minor issue.
It is possible that the degree of postoperative discomfort is operator-dependent, the experience of the radiation oncologist with the insertion technique being one possible factor. It seems unlikely that this would have affected our findings, given that all involved were essentially novices with respect to this procedure at the start of our program. our results however, may not necessarily be extrapolated to other institutions. Subsequent to this audit, and for unrelated reasons, we have changed to a HDR prostate brachytherapy regimen of two fractions with two catheter insertions separated by two weeks rather than the single insertion and three fractions over two days delivered to the patients described here. This allows each treatment to be a day-only procedure. The technique is otherwise similar, with the insertion carried out under general anaesthesia as described and the subsequent planning and dose delivery carried out with the patient conscious, and with a second radiation oncologist now performing some of the procedures. While we have to date made no further formal assessment, the analgesia requirements while the transperineal catheters remain in place appear not to have changed in any significant way.
In conclusion, we found that analgesic requirements during the period in which the prostate brachytherapy (and urinary) catheters remained in place were minimal in most cases. Our findings do not support the assertion of Collela et al 3 that epidural analgesic techniques are to be considered "best practice" for HDR prostate brachytherapy. Simple analgesic regimens (regular oral paracetamol, antispasmodics as required for bladder spasm and oral/subcutaneous opioids as required) appear to have sufficed for our patients and we cannot justify moving to more complex analgesic techniques for this procedure in our institution. Given the limitations of this study however, further assessment of the pain experienced during HDR prostate brachytherapy and the relevant modes of analgesia would be helpful.
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